Asset ClassPrivate Equity
Value of Investmenttba
Dama Pharmaceutical LLC, headquartered in Old San Juan, Peurto Rico was founded as a manufacturer of cannabis-based products and to develop an ecosystem to conduct clinical trials on product efficacy. Over the past year Dama has entered into four product licensing agreements and has begun development of its own products. While Dama maybe restricted to Puerto Rico when it comes to manufacturing, the Clinical Trial App maybe deployed anywhere to further the knowledge base of cannabis-based medicine through an open sourced decentralized autonomous organization (DOA)
The name Dama means medical cannabis in Chinese where it has been an integral part of medicine for over 4000 years.
It is DaMa’s intention to establish several standardized cannabis trial protocols, both for medical and recreational product which can be used anywhere by clinical practitioners to collect an ever-increasing amount of data on the effects of cannabis on humans. The data collection is owned by the trial sponsor, be it a physician, government organization, or a cannabis product manufacturer.
The altruism of creating a public body of knowledge on the effects of cannabis on humans is not lost by the economics of using the trials to generate sales.
Hyalolex product team from IGC at Natural Ventures facitlity in Caguas, Puerto Rico April 20th 2018
Among the most important use of funds is to invest in a state-of-the-art manufacturing facility complete with CO2 extraction and in-house broad-spectrum testing. DaMa is in discussions with one ideal facility.
STEPHEN INGLIS, Chief Executive Officer
Stephen is an investment banking pioneer in the legal cannabis industry going back to 2014 when listed companies first announced their plans for cannabis. Currently, Stephen is the CEO of InPortal Private Markets, a global cannabis market place.
After twenty years on Wall Street serving in senior roles at Morgan Stanley, Robert Fleming-JP Morgan, and as Head of Investment Banking for WestLB Pacific in Tokyo, Stephen founded Enclave Capital in 2007, growing it into America’s premier chaperone broker representing twenty-six foreign investment banks. During his tenure as CEO of Enclave Stephen was actively involved in life sciences including bringing pharmaceuticals and medical devices to market. In addition, as CEO at Enclave he formed a JV with Deep Value to operate one of two New York Stock Exchange sanctioned algorithms commanding sixty percent of floor traded volume.
Stephen is a Chartered Financial Analyst (CFA), and holds a Master’s in Economics from the University of British Columbia.